Immunity to Visceral Leishmaniasis
نویسندگان
چکیده
1 Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, 4 Raja, S. C. Mullick Road, Kolkata-32, West Bengal Kolkata 700032, India 2Faculty of Medicine, Addis Ababa University, P. O. Box 28017-1000, Addis Ababa, Ethiopia 3Departamento de Bioloǵıa Molecular Centro de Bioloǵıa Molecular “Severo Ochoa” C/ Nicolás Cabrera, 1 Universidad Autónoma de Madrid, 28049 Madrid, Spain 4Australian Centre for Vaccine Development, Queensland Institute of Medical Research, 300 Herston Road, Herston, QLD 4006, Australia
منابع مشابه
Post-kala-azar dermal Leishmaniasis in two different clinical contexts*
In Brazil, visceral Leishmaniasis is caused by Leishmania chagasi. The development of cutaneous lesions in visceral leishmaniasis patients has been described in two different clinical contexts. Patients with compromised immunity can develop skin lesions as a direct consequence of a current visceral disease. Equally, patients with a history of kala-azar and progressive, immune improvement occasi...
متن کاملImmunity and immunosuppression in experimental visceral leishmaniasis.
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, and visceral leishmaniasis is a form in which the inner organs are affected. Since knowledge about immunity in experimental visceral leishmaniasis is poor, we present here a review on immunity and immunosuppression in experimental visceral leishmaniasis in mouse and hamster models. We show the complexity of the mechanisms in...
متن کاملModels of relapse of experimental visceral leishmaniasis.
To establish models for studying recurrence of visceral leishmaniasis, a growing problem in T cell-deficient patients, two approaches were investigated: treatment of euthymic BALB/c mice with quiescent Leishmania donovani infection with T cell-depleting or anti-cytokine antibodies and serial observation of acutely infected nude BALB/c mice after an initial antileishmanial response induced by am...
متن کاملMaking an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
Visceral leishmaniasis is a major health problem in Latina America, as well as the Mediterranean region of Europe and Asia. We aimed to develop a vaccine against visceral leishmaniasis targeting the intracellular amastigotes, which is the parasite stage that persists throughout infections with Leishmania parasites. With this in mind, we identified an amastigote specific antigen (A2) that contai...
متن کاملCutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.
Visceral leishmaniasis (VL) is a fatal disease of the internal organs caused by the eukaryotic parasite Leishmania. Control of VL would best be achieved through vaccination. However, this has proven to be difficult partly because the correlates of protective immunity are not fully understood. In contrast, protective immunity against nonfatal cutaneous leishmaniasis (CL) is well defined and medi...
متن کاملDevelopment of Vaccines against Visceral Leishmaniasis
Leishmaniasis is a neglected disease resulting in a global morbidity of 2,090 thousand Disability-Adjusted Life Years and a mortality rate of approximately 60,000 per year. Among the three clinical forms of leishmaniasis (cutaneous, mucosal, and visceral), visceral leishmaniasis (VL) accounts for the majority of mortality, as if left untreated VL is almost always fatal. Caused by infection with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2012 شماره
صفحات -
تاریخ انتشار 2012